CFTR and cystic fibrosis: Another combination of drugs in one NLC‐based nanoparticle system was recently tested for the treatment of lung manifestation of cystic fibrosis (CF).[24] The system included lumacaftor for the correction of correct p.Phe508del mutation (the loss of phenylalanine at position 508) and CFTR potentiator ivacaftor for increasing the open probability of CFTR channels.